Use of n-acetyl-5-methoxytryptamine or analogues thereof, for promoting the mechanism of implantation of the embryo and related compositions and culture media

ABSTRACT

The present invention refers to the use of N-acetyl-5-methoxytryptamine (melatonin) and/or an analogue thereof, for use in the medical or veterinary field in the assisted reproduction for promoting the mechanism of implantation of the embryo, and in particular for the prevention of implantation failure into the uterus, by topical administration of an effective amount in a mammalian subject female in need of such treatment, and related compositions, culture media and medical devices.

The present invention relates to the use of N-acetyl-5-methoxytryptamine(melatonin) and/or an analogue thereof, for use in the medical orveterinary field in the assisted reproduction for promoting themechanism of implantation of the embryo, and in particular for theprevention of implantation failure into the uterus, by topicaladministration of an effective amount in a mammalian subject female inneed of such treatment, and related compositions, culture media andmedical devices.

The implantation of the human embryo into the uterus is a complexmechanism, which involves both the embryo, and the endometrialepithelium. The phases of apposition, adhesion and invasion involves amultiplicity of molecules, which play an unique role in the process, themolecular dialogue between the conceived and the endometrium impliesinteractions among cells, and between cells and biochemical factors.

These mechanisms, if suitably expressed or inhibited, are of help todetermine the receptivity or non-receptivity state of the endometriumversus the embryo.

The state of endometrial receptivity or non-receptivity, although it isa largely shared concept, is clinically hard to be defined: thehistological normality of the endometrium does not necessarily imply afunctional normality; on the other side, the time and space expressionof particular endometrial structures, named pinopodes, is stronglyindicative of the receptivity state itself.

The implantation is a complex sequence of signals which are crucial forsetting up pregnancy; it is supposed that a great number of molecularmediators under the influence of ovarian signals are involved in theembryo-endometrial interaction. These mediators comprise a wide range ofmolecules like hormones, cytokines, growth factors, lipids, adhesionmolecules and else (1).

Failure in the implantation in the technologies of medically assistedreproduction (MAR) still remains an unsettled problem and it isconsidered one of the main reasons of infertility in healthy women.Considering then that the percentage of implantation of the techniquesof MAR is of about 25%, the inadequate uterine receptivity is deemed asbeing responsible for about two thirds of all failures (for one thirdthe embryo is considered as being responsible) (2).

The endometrium is receptive of the invasion of blastocyst for a rangeof a limited time and defined as “window of implantation”. The“dialogue” for the synchronization between “ovulation-first phases ofembryonic growth—cell modifications of endometrial epithelium for theimplantation” is hold by a series of hormonal and biochemicalmessengers.

During the “implantation window”, the endometrial epithelium expresses,through hormonal and biochemical control, some structures namedpinopodes, capable to allow adhesion and invasion of blastocyst. Theimplantation window would be characterized, according to studies ofelectron microscopy (3) by the maximum expressivity of pinopodes.

The formation of pinopodes is considered as a specific marker of theendometrial receptivity, they appear about one week after ovulation, buttheir complete expression changes from patient to patient and seems tobe maintained for only one day (4).

The expression of pinopodes is directly proportional to the increase ofplasmatic levels of progesterone (5).

The concept of endometrial receptivity or “implantation window”,connected to the expression of pinopodes, unanimously accepted by thescientific community, is for some decades subject-matter of study forthe ones who face the problems related to assisted reproduction.

In summary: progesterone, the pro-gestation hormone, is the mainmediator and around it rotate a plurality of other mediators which maypromote the implantation occurrence.

From the aforesaid it comes out how the problem of obtaining pregnancythrough techniques of assisted reproduction is mostly ascribable to theshort knowledge of the implantation phenomenon.

It appears thus clear, also in view of the numerous legislativerestrictions in the field of assisted reproduction, the necessity tooptimize the phase of implantation.

The authors of the present invention have now found that one of themediators capable to have a key role along with progesterone in theexpression of pinopodes, with much positive effects for the embryonicnesting is N-acetyl-5-methoxy tryptamine (melatonin).

Melatonin is produced by the pineal, neuroendocrine gland controlled bylight; darkness stimulates its synthesis and secretion.

The use of melatonin has no side effects or overdose problems, as wellas no contraindication (6) is reported in literature.

Many are the advantages already known and associated with the use ofmelatonin also in different processes, which may positively interferewith the implantation. In this respect, it exists moreover an inverselyproportional correlation with the risk of carcinoma of the endometriumand the serum levels of melatonin with ascertained protective action.

It has been proved by some authors (7) that melatonin inhibitsproliferation of atypical endometrial cells, defined as Ishikawa,responsible for carcinoma of the endometrium. Through experiments withradioligands and antagonists of melatonin such as luzindole, the resultsof the group of researchers have proved that the inhibition effect isproduced by melatonin through the MT2 receptors present in the membranesof the proliferative cells of Ishikawa.

Another determinant aspect to consider is the menopause period, duringwhich melatonin diminishes its production and, indeed, during such aperiod the risk of endometrial carcinoma is higher.

For example, in vitro and in vivo (6, 8) studies have shown a strongantioxidant action of melatonin, said action being higher than that ofmannitol, of glutathione and vitamin E in the protection from oxidativedamage due to hydroxyl toxic radicals and to other catabolic cellproducts deriving from variations in the degenerative or proliferativemetabolism and from/for lipid oxidation.

Melatonin (9-10) has moreover important anti estrogenic properties andstimulates production of progesterone which is in antithesis with theaction of estrogens themselves (high levels of estrogens associate witha worst result in the techniques of assisted reproduction) (11).

In this regard, it is pointed out that super-ovulation throughgonadotropins induced in MAR cycles, determines a hyperestrogenizationwith increase of endometrial hyperplasia, a significant risk factor forendometrial carcinoma as above mentioned.

Some authors (12) affirm that it exists a synergism between humanchorionic gonadotropins (hCG) and melatonin: indeed, melatoninincreases, by increasing inter alia the production of progesterone (bothin vivo and in vitro), 6-7 days after the ovulatory peak of hCG.

In this regard it is highlighted how the post-ovulatory peak ofmelatonin perfectly coincides with the endometrial implantation windowand with the formation of blastocyst (the step of embryonic growth inwhich the nesting into the uterus occurs). The positive correlationbetween melatonin and progesterone and the negative correlation betweenmelatonin and estradiol would be enhanced by hCG: indeed, in the absenceof the latter, melatonin has a very weak effect on production ofprogesterone.

An object of the present invention is N-acetyl-5-methoxy tryptamine oran analogue thereof, for use in the medical or veterinary field inassisted reproduction for the prevention of implantation failure intothe uterus by topical administration of an effective amount in amammalian subject female in need of such treatment.

Preferably, said analogue of N-acetyl-5-methoxy tryptamine is selectedfrom agomelatine, 6-hydroxymelatonin, serotonin, 5 hydroxytryptophan ortheir derivatives.

In a preferred embodiment of the invention the mammalian subject femaleis a woman suffering from infertility or polyabortion.

According to a further preferred embodiment, the topical administrationof N-acetyl-5-methoxy tryptamine or an analogue thereof, preferably ofN-acetyl-5-methoxy tryptamine, takes place through endometrialirrigation or uterine washing or endometrial washing.

Still according to a further preferred embodiment of the invention, saidtopical administration occurs in a single administration at the time ofoocyte retrieval.

Preferably, said active principle is present in a concentration rangingfrom 4×10⁻⁹ g/ml to 25×10⁻⁹ g/ml, still more preferably greater than orequal to 10×10⁻⁹ g/ml.

In an alternative embodiment, it is possible the concurrent use with asystemic therapy based on N-acetyl-5-methoxy tryptamine, hCG orprogesterone, or a combination thereof, from the day of oocyteretrieval.

In alternative preferred embodiments of the present invention, thetechniques of assisted reproduction are selected from the groupconsisting in basic or of I level techniques, simple and not muchinvasive as targeted intercourse or intrauterine artificial inseminationand II or III level techniques, which are more complex and invasiveselected from in vitro fertilization (IVF), in vitro fertilization andembryo transfer (FIVET), intracytoplasmic sperm injection (ICSI),intracyitoplasmic morphologically selected sperm injection (IMSI) andTese-Tesa techniques (Testicular Sperm Aspiration-Extraction).

Artificial fertilization stands mainly for the technique of intrauterineinsemination (IUI), which is a technique of medically assistedreproduction, wherein the seminal fluid is introduced inside the uterinecavity. It may be suggested in all those cases of incompatibilitybetween cervical mucus and seminal fluid, in that it allows to go beyondthe cervical length and insert spermatozoa directly into the uterus. Itis moreover used in case of unexplained sterility, of male infertilityof light or moderate degree, in cases of reiterated failures in theinduction of pregnancy with stimulation of ovulation and targetedintercourse and in cases of sexual disorders which do not allow acomplete sexual intercourse.

In vitro fertilization and embryo transfer (FIVET) is a MAR techniquewherein human gametes are withdrawn, placed under culture and, afterfertilization and production of one or more embryos, these aretransferred into the uterus. This technique is suggested in cases of:

-   -   Acquired or congenital tubal pathology;    -   male infertility of moderate degree;    -   endometriosis of III or IV level;    -   unexplained infertility;    -   cryo-preserved semen in relation to the seminal quality,        subsequent to thawing;    -   failing of the therapeutic procedure of I level techniques.

After ovarian stimulation, oocytes retrieval (PICK-UP) is carried outvia transvaginal operation, under echographic control, in localanaesthesia and/or deep sedation, a preparation of the sperm is effectedand the oocytes to be fertilized are selected. Next, the extracorporealculture of gametes is prepared and after verifying the occurredfertilization, the transfer into the uterus of a definite number ofembryos is performed.

The intracytoplasmic sperm micro-injection (ICSI) uses various steps ofthe FIVET. Also in this case the fertilization is extracorporeal, but ittakes place with the injection of a single spermatozoon inside thecytoplasm of the oocyte. Then, after the occurred fertilization, theembryos are transferred into the uterus.

This technique is suggested in cases of:

-   -   male infertility of severe degree;    -   occlusive and secretive azoospermia (testicular spermatozoa or        epididymis);    -   failed or reduced fertilization in previous cycles of in vitro        fertilization (IVF);    -   thawed oocytes;    -   reduced number of oocytes;    -   cryo-preserved semen in relation to the seminal quality        subsequent to thawing.

Also this technique can be carried out under spontaneous cycle orthrough induction of multiple follicular growth and after havingstimulated the ovary to produce more follicles and so having obtainedmore oocytes, oocyte retrieval (PICK-UP) is carried out via transvaginaloperation. Contemporaneously to PICK UP, preparation of the sperm iseffected. In case of azoospermia, the techniques used for withdrawal ofspermatozoa are: Testicular Sperm Percutaneous Aspiration (TESA),Testicular Sperm Extraction (TESE), Microchirurgical Epididymal SpermAspiration (MESA), Percutaneous Epididymal Sperm Aspiration (PESA).

Subsequently, the preparation of the oocyte and the insemination ofoocytes through intracytoplasmic micro-injection technique of a singlespermatozoon takes place. After verifying the occurred fertilization ofeach oocyte, the embryos are transferred into the uterus.

It is a further object of the present invention a composition suitablefor topical administration comprising N-acetyl-5-methoxytryptamine or ananalogue thereof, or their combination as active ingredient, in aneffective amount in a mammalian subject female in need of suchtreatment, along with one or more physiologically acceptable excipientsor adjuvants, for use in the medical or veterinary field in the assistedreproduction for the prevention of implantation failure into the uterus.

Preferably, said active ingredient is present in the composition in aconcentration ranging from 4×10⁻⁹ g/ml to 25×10⁻⁹ g/ml, preferablygreater than or equal to 10×10⁻⁹ g/ml.

According to a preferred embodiment, the active ingredient in the abovementioned composition is formulated as endometrial/uterusirrigation/washing in a cell culture medium in a final concentrationranging from 4×10⁻⁹ g/ml to 25×10⁻⁹ g/ml, preferably greater than orequal to 10×10⁻⁹ g/ml. Such a culture medium for blastocyst maypreferably comprise the following components:

-   -   source of D-glucose;    -   Antibiotic, preferably gentamicin;    -   Human serum albumin;    -   Essential and non-essential amino acids, preferably L-taurine;    -   buffer salts preferably selected between:    -   Calcium salts: calcium lactate, calcium pantothenate;    -   Sodium salts: sodium chloride, sodium bicarbonate and sodium        pyruvate;    -   Potassium salts: potassium chloride, potassium phosphate;    -   Magnesium salts: magnesium chloride, magnesium sulphate        and mixtures thereof;    -   Water;        and has a pH between 7.5 and 7.8.

According to a preferred embodiment said culture medium may be SydneyIVF® Blastocyst medium.

According to an alternative embodiment of the present invention, theactive ingredient of the above mentioned composition is formulated asendometrial irrigation, endometrial washing or uterine washing inphysiological solution with a final concentration ranging from 4×10⁻⁹g/ml to 25×10⁻⁹ g/ml, preferably greater than or equal to 10×10⁻⁹ g/ml.

In females, the procedure of washing of the uterine cavity has beencommonly used with the main objective to set non-invasive prenataldiagnosis, innovative with respect to invasive traditional methods ofamniocentesis and chorionic villus sampling [(13)(14)]. In recent years,such technique has been applied to evaluate the conditions of theuterine cavity before the transfer of the embryo in the cycles ofassisted reproduction. The application of this procedure consists in theinsertion into the uterus of a buffer solution with the aim atcollecting uterine secretes and evaluate their organic and inorganicbiological components. It has the purpose to identify possible markers,predictive of implantation success [(15)(16)(17)(18)].

Still preferably, said composition suitable for topical administrationthrough uterine washing further comprises essential and non-essentialamino acids, and buffer salts. Preferably said buffer salts are salts ofcalcium, sodium, potassium and magnesium, and mixtures thereof. The useof buffer salts and amino acids is provided for producing a formulationwith a pH comprised between 7 and 8 (preferably between 7.5-7.8), toreplicate the micro-environment suitable for the embryo (and similar tothat of culture media in which the embryo grows before the transfer intothe uterus).

According to an alternative embodiment, the compositions of theinvention may be formulated as gel suitable for uterine administration,more precisely for in situ administration in the uterine cavity,preferably with a medical device being an intrauterine “T shaped”device. It is also possible to foresee controlled release gelformulations for mucosal administration.

Considering that the uterine washing technique as above describedrevealed to be a non-invasive practice and that allows restoration ofthe uterine physiological conditions through mechanical removal ofsecretes, which may alter the implantation conditions, the invention hasas a further object a medical device for uterine washing comprising asterile container pre-filled or to be filled with a composition as abovedefined.

More precisely, the device according to the present invention can befilled at the moment of use with a sterile solution suitable for theuterine or endometrial washing supplemented with the active principlemelatonine or analogue thereof according to the present inventionalready formed or it can be filled with such sterile solutionsupplemented just at the moment of use with the active principle.

According to a preferred embodiment the sterile container is disposable.More preferably the sterile container (preferably a disposable sterilecontainer) is pre-filled with physiological solution supplemented withmelatonin (in a concentration ranging from 4×10⁻⁹ g/ml to 25×10⁻⁹ g/ml,preferably greater than or equal to 10×10⁻⁹ g/ml), buffer salts andamino acids such as to produce a formulation with pH comprised between7-8, preferably between 7.5 and 7.8.

The uterine washing shall be performed with the aid of a catheter afterpick-up with echographic guide. The next embryos transfer orimplantation shall take place averagely three days after the washing(2-5 days).

Therefore, according to preferred embodiments of the invention themedical device according to the invention may further comprise a sterileflexible catheter, preferably with a single terminal hole.

The sterility of the medical device components is achieved preferablythrough sterile filling or final sterilization, such as heatingtreatment or through gamma rays treatment.

In addition, the medical device can be accompanied by instructions foruse in the various MAR techniques.

The purpose of the medical device is that of removing oxidant substancesand possible secreted products in response to the stimulation precedingthe MAR techniques and thus of restoring the physiological compositionof the endometrial exudate. The objective is that of avoiding that suchoxidizing substances and secreted products reduce the percentage ofimplantation in patients subjected to MAR. As above anticipated, the useof buffer salts and amino acids is provided for setting a pH comprisedbetween 7-8, preferably between 7.5 and 7.8, for replicating themicro-environment suitable for the embryo. The addition of melatonin,additional to the effects shown within the present invention, exerts avery strong antioxidant effect and a safety action versus endometrialcells, of the oxidative damage due to toxic radicals and other catabolicproducts.

Preferably, said disposable sterile container is selected from syringe,dispenser, cartridge for self-injection/pen.

According to particularly preferred embodiments of the invention thesyringe is of the luer-lock type 3 ml made of polycarbonate orborosilicate glass. When a syringe of the luer-lock type is used, theintrauterine catheter possibly associated with the medical deviceaccording to the invention is provided with a luer lock female joint forcoupling with the syringe.

Alternatively, if a self-injection system or a pen is used (insulintype) it can be used a glass cartridge 3 ml of borosilicate glass.

Still preferably said disposable sterile container is pre-filled withvolume of 1.5 ml of washing solution containing:

-   -   10×10⁻⁹ g/ml (10 ng/ml) of melatonin    -   essential and non-essential amino acids    -   calcium salts    -   potassium salts    -   magnesium salts        a pH comprised between 7.5-7.8 and osmolarity comprised between        280-290 mOsm/kg.

The invention has also as an object the medical device as aboveillustrated for use in a single administration as endometrial washing atthe moment of the oocyte retrieval in protocols of medical assistedreproduction.

The invention also refers to a cell culture medium in vitro or in vivo,comprising the following components:

-   -   source of D-glucose;    -   Antibiotic, preferably gentamicin;    -   Human serum albumin;    -   Essential and non-essential amino acids, preferably L-taurine,    -   Calcium salts: calcium lactate, calcium pantothenate;    -   Sodium salts: sodium chloride, sodium bicarbonate and sodium        pyruvate;    -   Potassium salts: potassium chloride, potassium phosphate;    -   Salts of magnesium: magnesium chloride, magnesium sulfate;    -   Water;        characterized in that it further comprises N-acetyl-5-methoxy        tryptamine or an analogue thereof, or their combination, wherein        said active ingredient is present in a concentration ranging        from 4×10⁻⁹ g/ml to 25×10⁻⁹ g/ml, preferably greater than or        equal to 10×10⁻⁹ g/ml.

It stands for a further object of the present invention a cell culturemedium for the expansion of pinopodes and the achievement of an in vitromodel study.

Such a cell culture medium can be used also for embryonic cultures, byachieving for example a culture medium which is used for transferringthe embryo into the uterus, said medium being thus inserted into theuterus.

Particularly advantageous aspects of use according to the presentinvention are connected to the proposed route of topical administration,which does not compromise the MAR treatment cycle, being such a routemuch less invasive than endometrial biopsy, already applied to womensubjected to a cycle of MAR (13).

At last, thanks to the properties of synthesis inhibition by side ofprostaglandins (14), which are typical of melatonin, this washingreduces uterine contractions and further promotes implantation.

The present invention will be now described in an illustrative manner,but not limitative, according to two preferred embodiments, withparticular reference to the annexed figures, wherein:

FIG. 1 illustrates the endometrium before treatment through thecomposition according to the present invention, therefore in the absenceof pinopodes;

FIG. 2 illustrates the endometrium 1/2 days after treatment through thecomposition according to the present invention: the formation ofpinopodes starts to come into sight;

FIG. 3 illustrates the endometrium 3/4 days after treatment through thecomposition according to the present invention: maximum growth ofpinopodes;

FIG. 4 illustrates the endometrium 5/6 days after treatment through thecomposition according to the present invention: it starts cleavage ofpinopodes, which appear to be irregular (cell apoptosis).

FIG. 5 shows the results of the FACS analysis (fluorescence intensitymeasurement) of the antioxidant activity of melatonin, agomelatine and6-hydroxymelatonin (170 nM corresponding to 40×10⁻⁹ g/ml) carried out atH₂O₂ concentrations of 20 μM and 200 μM;

FIG. 6 shows the results of apoptosis assay (% cell death) carried outat different concentrations (80 nM, 170 nM, 340 nM; correspondingrespectively to 18×10⁻⁹ g/ml, 40×10⁻⁹ g/ml, 80×10⁻⁹ g/ml) of melatonin,agomelatine and 6-hydroxymelatonin.

Merely for example, but not limitative of the present invention,hereinafter are reported the comparative studies carried out (in vitroand in vivo) by the authors of the present invention to evaluate thepercentage increase of human embryonic implantation in MAR techniquesthrough the use of melatonin in different solutions.

EXAMPLE 1 In Vivo Studies Materials and Methods Solutions of MelatoninUsed for Endometrial Washings

The melatonin (or N-acetyl-5-methoxy tryptamine; CAS Number 73-31-4)used has been obtained at Farmalabor as product in form of powder withtitle ≧99%.

Two clinical trials have been carried out providing the administrationof melatonin (concentration 10×10⁻⁹ g/ml) through endometrial washingin:

-   -   1) culture medium Sydney IVF® Blastocyst medium (Clinical        trial 1) supplied by Cook Ireland Ltd (Catalogue Number G20722        and G20929). Said culture medium is normally used to improve        cleavage, differentiation and expansion in vitro of blastocyst.        The medium contains D-glucose, all the 20 essential L-amino        acids, L-taurine, Gentamicin, human serum albumin, calcium        lactate, calcium pantothenate; sodium chloride, sodium        bicarbonate and sodium pyruvate; potassium chloride, potassium        phosphate; magnesium chloride, magnesium sulfate; purified        water. Further characteristics of the culture medium:    -   pH: 7.5-7.8 (use of bicarbonate buffer)    -   Osmolarity: 280-290 mOsm/kg    -   Endotoxins: <0.4 EU/ml    -   MEA: ≧80%

2) Physiological Solution (Clinical Trial 2)

Statistical Analysis:

It has been carried out a statistical analysis (IMPRUN.TXT) of linearregression with more variables.

Statistical Methods:

The role of the number of implanted embryos, of their quality and of thewashing process with the solution containing melatonin in the increasingof the chance of pregnancy has been computed by means of non-conditionallogistic regression, by adjustment according to the mother's age.

The ratio between the chance of pregnancy associated with each procedure(number of embryos, their quality and application of the washing processwith saline solution or Blastocyst medium containing melatonin) and thechance of pregnancy with reference respectively to the lower category ofnumber of embryos (one), to the quality less than optimal of implantedembryos, or to the absence of the washing process, has been defined asOdds Ratio (OR), and it has been computed through non-conditionallogistic regression, by adjustment according to the mother's age.

In the logistic regression, OR corresponds to the antilogarithm on anatural basis of the regression coefficient β associated with eachcovariate in the regression model.

The value thus calculated expresses therefore the advantage obtainedthrough each procedure, irrespective of the other conditions.

The two-tailed confidence intervals at 95% (IF95%) of the OR have beencalculated through the formula of Wald (eβ±(z_(e/2)*se_(β))).

Sterility Controls (Culture Medium)

To carry out the sterility controls of the culture medium supplementedwith melatonin it has been used the BACT/ALERT 3D-60 device(BIOMERIEUX). The bottles of Bact/ALERT culture are applied to systemsof microbial detection in qualitative procedures for recovering anddetecting optional anaerobic and aerobic (bacteria) in the blood andother fluids normally sterile as the Blastocyst medium used in thepresent experimentation.

The Bact/ALERT system of microbial detection is used to determinewhether microorganisms are present in the samples of blood or of otherfluids normally sterile as the blastocyst medium used in our invention,with suspected bacteremia. The Bact/ALERT system and the culture bottlesoffer a system of microbial detection and a culture medium withenvironmental and nutritional conditions suitable for microorganismscommonly present in blood infections and other fluids normally sterile.

The inoculated bottles (from a minimum of 5 ml to a maximum of 10 ml ofsample at issue) are incubated in the device, where they are subjectedto continuous monitoring in order to detect a possible growth ofmicroorganisms in the Bact/ALERT bottles.

The Bact/ALERT system of microbial detection uses a colorimetric sensorand reflected light for monitoring the presence and the production ofcarbon dioxide (CO₂) dissolved in the culture medium.

The microorganisms possibly present in the sample metabolize thesubstrates in the culture medium producing carbon dioxide. Theproduction of CO₂ determined by the growth of microorganisms induces thegas permeable green-blue sensor present on the bottom of each culturebottle to take a yellow colour.

The lighter colour indicates an increase of the units of monitoringreflectance of the system.

The reflectance of the bottle is monitored and traced by the deviceevery 10 minutes.

The culture bottles are established as being positive or negative by themanaging software of Bact/ALERT systems of microbial detection after 6days of incubation.

No intervention is necessary up to the moment in which the Bact/ALERTdevice alerts that a culture bottle is positive or negative.

Before carrying out any endometrial irrigation culture tests have beencarried out for testing sterility in 2-4-6 days and once the negativeculture was found it was used into the uterus.

Criteria of Inclusion Restricted criteria of inclusion have been usedfor selecting the patient population involved in the studies:

-   -   3) age ≧20 and <44 years    -   4) body mass index (BMI) ≧20 and ≦28 kg/m²    -   5) Basal FSH ≦19 UI/l    -   6) Male and female factors

Patients

The patients involved in all the two clinical studies, after collectinginformed consent, have been subjected to assisted reproduction.

In this first two-arms randomized multi-centre clinical study (controland study group) involved about 430 patients/arm.

The patients undergoing assisted fertilization have been randomized theday of oocyte retrieval in three groups:

Group A: 430 patients to be subjected to endometrial irrigation with 1.5ml of physiological solution (controls).Group B: 436 patients to be subjected to endometrial irrigation with asolution of 1.5 ml of culture medium supplemented with finalconcentration of melatonin (10×10⁻⁹ g/ml).Group C: patients not subjected to endometrial irrigation.

The study has been carried out involving patients in several privatecenters specialized in MAR, such as the Center of BRA, the Promea Centerof Torino and Cagliari, the Genera Center of Perugia and the polyclinicPublic Center of Bari. To these centres it has been sent the culturemedium supplemented with melatonin after having been subjected tosterility tests to carry out the following protocol of treatment.

After in vivo enrolling for assisted fertilization by endometrialirrigation with known concentration (final concentration of 10×10⁻⁹g/ml) of melatonin at the time of oocyte retrieval, patients weresubjected to related ultrasound-guided visualization of the diameter ofliquid stratum created on the bottom of the uterus.

The second clinical study with a single prospective centre involved 64patients in the group of control and 92 patients in the group of study.

In said study melatonin has been administered in sterile physiologicalsolution, through endometrial washing inside the uterine cavity ofpatients, following to oocyte retrieval.

Endometrial Washing

Briefly, the treatment consists in endometrial irrigation inside theuterine cavity without any cell in co-culture, using the physiologicalsolution or the culture medium admixed with melatonin with finalconcentration of 10×10⁻⁹ g/ml (preceding studies had been effected withone third and the half of the final concentration then maintainedwithout giving the same results—not shown data).

After oocyte retrieval, (the time correspondent to the ovulation afterthe administration of hCG in the protocols of MAR) after havingcontrolled the vaginal homeostasis, it has been jointed a sterilesyringe from 2.5 ml to a single-lumen intrauterine catheter with apicalopening and the culture medium (Blastocyst medium) or the physiologicalsolution has been suctioned, modified through addition of melatonin upto a volume of 1.5 ml.

In the case of the physiological solution, the catheter can bepre-filled with physiological solution supplemented with melatonin.

The catheter has been introduced in the internal uterine orifice withthe same steps through which the operator carries out the conventionalembryo-transfer (ET).

Then, it has been slowly injected the saline solution supplemented withmelatonin or the modified medium and, at the end of irrigation, thethickness of the endocavitary liquid stratum has been measured bytransabdominal echography (washing and echography must be simultaneous,the liquid stratum arrives at about 10 mm and then quickly disappears).

Results Clinical Study 1

The multi-centre in vivo study involved 863 patients subjected toassisted fertilization and to endometrial irrigation (echographicmeasurements of the liquid stratum) with melatonin and 3-4 days afterthat, they have been subjected to embryonic transfer. For the latter,the CI (confidence interval or trust interval) has been calculatedthrough statistical analysis (IMPRUN. TXT) of linear regression withmore variables of 95%.

The univariate analysis shows that the implantation of 3 embryos impliesa significant increase, equal to about 3 times (OR=2.8, IF 95% 1.7-4.4)the chance of pregnancy.

A number of two embryos does not appear instead to be sufficient toincrease the chance of pregnancy (OR=1.0, IF 95% 1.7-4.4).

On the other hand, also the optimal quality of the implanted embryosseems to be an important factor in increasing the chance of pregnancy(OR=2.9, IF 95% 1.8-4.7). In the univariate analysis, the same rate ofrelevance appears to be associated with the use of the irrigationprocedure (OR=2.2, IF 95% 1.6-2.9).

The multivariate analysis allows to control the independent effect ofeach variable, therefore totally irrespective of the effect of the otherapplied procedures and of the mother's age. In this case, the use of thewashing procedure doubles the chance of success of pregnancy (OR=2.2, IF95% 1.6-3.0).

A similar improvement appears to be associated with the implantation ofthree embryos, rather than the implantation of a single embryo (OR=2.1,IF 95% 1.2-3.7), and to the use of embryos of optimal quality (OR=1.9,IF 95% 1.1-3.3).

The use of all the three procedures as above reported seems to betherefore the best choice in the procedures of assisted fertilization.

In conclusion, the in vivo studies have proved that the irrigation orthe washing with melatonin of endometrial cells allows to double thenumber of pregnancies with respect to the other two groups, which didnot differentiated significantly.

Clinical Study 2

The single centre study involved 64 patients in the group of control and92 patients in the group of study.

The patients have been subjected to assisted reproduction and toendometrial washing (echographic measurements of the liquid stratum)with melatonin in sterile saline solution, and 3-4 days after they havebeen subjected to embryonic transfer.

The primary endpoint of the study is the rate of clinical pregnancies(fetal heart) due to embryonic transfer (ET); the secondary endpoint isthe rate of ongoing pregnancies and aborts.

The rate of clinical pregnancies resulted to be equal to 37% in thegroup of study vs 17.2% in the group of control, whereas the rate ofongoing pregnancies resulted to be equal to 32.6% in the group of studyvs 14.1% in the group of control.

The results have been reported in the following Table 1.

TABLE 1 CONTROL WASHING No (%) No (%) No ET 64 92 Age (years ± SD) 38.8± 1.2  36 ± 4  No embryos 2.7 ± 1.1  2.5 ± 1.08 transferred (Average ±SD) No embryos 1.5 ± 1   1.3 ± 0.8 Grade A (Average ± SD) No embryos 0.9± 0.7 1.17 ± 0.8  Grade B (Average ± SD) No embryos 0.2 ± 0.5 0.1 ± 0.3Grade C (Average ± SD) Day ET 3.5 ± 0.5 3.5 ± 1.2 (Average ± SD) BHCGPositive 12 18.8% 41 44.6% (on total of ET) Clinical 11 17.2% 34 37.0%Pregnancy/ET Ongoing 9 14.1% 30 32.6% Pregnancy/ET Aborts 1 9.1% 4 11.8%

The endometrial washing carried out with the various solutionscontaining melatonin, allows to double the rate of clinical pregnanciesand ongoing pregnancies vs the group of control in the infertile femalepopulation.

The data seem to confirm that the removal of endometrial exudate usingthe physiological solution with melatonin can create a physiologicalendometrial environment and improve implantation success.

This allows to obtain a valid and innovative means for increasing theimplantation rates in assisted reproduction technologies (ART).

EXAMPLE 2 In Vitro Study Materials and Methods

The melatonin and the culture medium used are the same as those used forthe in vivo study.

Electron Microscopy (SEM)

It has been used a field emission at high resolution electronmicroscope, FE HITACHI S 4000 model, operating at 15-20 KW.

Preparation of Samples

Soon after retrieval from the patient, small pieces of endometrialtissue of about 1 mm in size have been placed in a fixing solutioncomposed of paraformaldehyde 1% and glutaraldehyde 0.5% in buffercacodylate 0.1 M pH 7.2 for 3 hours.

After this fixing the pieces are washed in PBS 20 min×3 times (1 hourtotal) and then the post fixing is carried out in a solution of osmiumtetroxide 2% and potassium ferrocyanide 2.5%.

The preparation is kept in the dark for 3 hours to be then accuratelywashed rotating in PBS, with 4 replacements of 20 min each.

It follows dehydration of the samples of tissue with acetone inascending succession with 3 replacements in 1 hour for each gradation50%-70%-80%-90%-95% and 2 replacements with pure acetone.

At this stage it follows drying up to the critical point with liquid CO₂in the apposite high-pressure device which substitutes acetone 10% withliquid CO₂, it is then slowly brought to the critical point temperatureand CO₂ evaporates. At this point the samples of tissue are perfectlyanhydrous and can be arranged on the trays of the electron microscope.

The samples are fixed through a special electrically conductive doublesided adhesive and for their arrangement two very thin needles are usedand the preparation is ready to be observed with scanning electronmicroscope (SEM).

Biological Samples

Under prior informed consent, they have been placed under culturefragments of endometrium withdrawn from patients subjected to diagnostichysteroscopy.

For each patient, two parts have been set: one part of the tissue hasbeen placed under culture through a conventional Blastocyst Medium voidof melatonin, the other part through a conventional Blastocyst mediumsupplemented with melatonin.

Culture Set

In vitro culture of endometrium (withdrawn through hysteroscopy frompatients subjected to assisted pre-fertilization controls) withmelatonin for 3-6 days and correlated visualization of pinopodes throughelectron microscopy (SEM).

Results

In vitro studies have shown that the co-culture from 3 to 5 days ofendometrial tissue in test-tube with permanent addition of melatonin,involves an unquestionable increase of pinopodes (under electronmicroscopy (SEM)), irrespective of the age of the patient and of themenstrual cycle phase in spontaneous cycles or manipulated throughpharmacological stimulation of super-ovulation, with respect to theculture of control. Such pinopodes are structures which are defined asthe most important implantation marker which for each woman (with avariability of 5 days, that is, a woman can menstruate after 26 dayswith short cycle or menstruate after 33 days) is of 48 hours. In fact,two thirds of success of becoming pregnant depends on the correct momentof implantation, the other third depends on the quality of the embryo.

The examination under the electron microscope SEM has shown that theaddition of melatonin leads to a complete morphological expression ofpinopodes as illustrated in FIGS. 1-4.

This outlines the importance of pinopodes during the implantation windowand the increase of their expression induced in culture through mediumssupplemented with melatonin.

EXAMPLE 3 Study on the Effects of Melatonin and Analogues on Oxidationand Apoptosis of Endometrial Cell Line HEC-1-A Tested Compounds

The analogues of melatonin which has been used for Comparison withmelatonin (M5250), are agomelatine (A1362) and 6-hydroxy melatonin(H0627), all purchased from Sigma Aldrich.

They were used in different concentrations (i.e. 40 nM, 80 nM, 170 nMand 340 nM, corresponding respectively to 9.4×10⁻⁹ g/ml, 18×10⁻⁹ g/ml,40×10⁻⁹ g/ml and 80×10⁻⁹ g/ml).

Cell Line

HEC-1A cells were obtained by ATCC and culture following instructions ofthe provider.

HEC-1-A is an epithelial stabilized cell line isolated by H. Kuramotofrom adenocarcinoma patient (21), which provide a valuable model tostudy endometrial epithelial cell in vitro (22).

Antioxidant Activity Assay

The HEC-1-A cell line was cultured with 170 nM (40 ng/ml) of Melatonin,6-hydroxy-melatonin and agomelatine and two different concentrations ofH₂O₂ (20 and 200 mcg/ml).

Reactive Oxidative Substances (ROS) were measured by FACS as previouslydescribed by Italiano et al. (23) in two independent replicates.

Results

Melatonin and the two analogues asserted the same anti-oxidative effect,on the in-vitro cell line model, at the H₂O₂ concentration of 20 mcg/ml.

When the H₂O₂ concentration is increased up to 200 mcg/ml melatonin andagomelatine continued to protect cell line from oxidation, whereas the6-hydroxy-melatonin does not. However, increasing the6-hydroxy-melatonin dose up to 340 nM the anti-oxidative effect of thisanalogue is reached (data not shown).

Results are illustrated in the chart of FIG. 5.

These results are in line with data published by Duan et al. (24) on theanti-oxidative effect of melatonin in a different cell model anddemonstrate that melatonin and analogues assayed have a similar effectat least when 20 mcg/ml of H₂O₂ is used on endometrial cell line.

Apoptosis Assay

The apoptosis (% cell death) of the endometrial cells is a physiologicalphenomenon generally observed at 10-20% rate during cell culture.

In order to determine if melatonin and its analogs induce cell death inthis specific experimental context, we have treated the HEC-1-A cellline with 340 nM (80 ng/ml), 170 nM (40 ng/ml) and 80 nM (18.8 ng/ml) ofmelatonin, 6-hydroxy-melatonin and agomelatine, respectively, for 24hours.

Apoptosis levels were assayed by Propidium Iodide staining and FACSanalysis. Percentage of sub-G1 events is shown for one of twoexperiments performed.

Results

In all the concentrations tested, Melatonin exerts a protective effecton apoptosis. Agomelatin has a protective effect at 170 and 340 nM,while no effect on apoptosis is shown by 6-hydroxy-melatonin up toconcentration of 170 nM. Results are shown in FIG. 6.

BIBLIOGRAPHY

-   1. Simon C, Martin J C, Pellicer A. Clin obst & gynaecol, 2000    14; (5) 127: 815-826.-   2. Lédéé-Bataille N, Laprée-Delage G, Taupin J L, Dubanchet S,    Frydman R, Chaouat G. Hum Reprod, 2002 Jan. 17; (1): 213-218.-   3. Nardo L G, Sabatini L, Rai R, Nardo F. Eur J Obstet Gynecol    Reprod Biol, 2002 Mar. 10; 101 (2): 104-8.-   4. Nikas G, Makrigiannakis A. Ann N Y Acad Sci, 2003 November; 997:    120-3.-   5. Stavreus-Evers A, Mandelin E, Koistinen R, Aghajanova L, Hovatta    O, Seppala M. Fertil Steril, 2006 June; 85 (6): 1803-11. Erratum in:    Fertil Steril. 2006 August; 86 (2): 498.-   6. Brzezinski A. N Engl J Med, 1997 Jan. 16; 336 (3): 186-95.-   7. Kobayashi Y, Itoh M T, Kondo H, Okuma Y, Sato S, Kanishi Y,    Hamada N, Kiguchi K, Ishizuka B. J Pineal Res, 2003 September; 35    (2): 71-4.-   8. Aydogan S, Yerer M B, Goktas A. Melatonin and nitric oxide. J    Endocrinol Invest, 2006 March; 29 (3): 281-7.-   9. Sandyk R, Anastasiadis P G, Anninos P A, Tsagas N. Int J    Neurosci, 1992 February; 62 (3-4): 243-50.-   10. Sandyk R, Anastasiadis P G, Anninos P A, Tsagas N. Int J    Neurosci, 1992 January; 62 (1-2): 89-96.-   11. Simón C, Garcia Velasco J J, Valbuena D, Peinado J A, Moreno C,    Remohi J, Pellicer A. Fertil Steril, 1998 August; 70 (2): 234-9.-   12. Tang P L, Chan T Y, Tang G W, Pang S F. Gynecol Obstet Invest.,    1998; 45(4):247-52.-   13. Cioni et al., Prenat Diagn. 2005; 25/3(198-202).-   14. Bussani C. et al, Mol Diagn Ther. 2007.-   15. Florio et al., Fertil Steril. 2010.-   16. Hannan N J, et al. Reprod Sci. 2012; 19:1125-32.-   17. Giulini S. et al. Arch Gynecol Obstet. 2012; 285:1479-1482.-   18. Berlanga S. et al., Placenta 2011; 32 Suppl. 3:S271-5.-   19. Ubaldi F, Bourgain C, Tournaye H, Smitz J, Steirteghem A,    Devroey P. Fertil Steril, March 1997 67, 3: 521-526.-   20. Schaeffer H J, Sirotkin A V. Adv Exp Med Biol. 1995;    395:547-548.-   21. Kuramoto H, et al. Am. J. Obstet. Gynecol. 114: 1012-1019, 1972.-   22. Mo B. et al, 2006) Mo B, Vendrov A E, Palomino W A, DuPont B R,    Apparao K B, Lessey B A. Biol Reprod. 2006; 75(3):387-94.-   23. Italiano D., Lena A M, Melino G, Candi E. Cell Cycle. 2012;    11(24):4589-96.-   24. Duan W., et al. PLoS One. 2013; 8(3) Epub 6 Marzo 2013.

1. N-acetyl-5-methoxy tryptamine or an analogue thereof, for use in themedical or veterinary field in assisted reproduction for the preventionof implantation failure into the uterus by topical administration of aneffective amount in a mammalian subject female in need of suchtreatment.
 2. N-acetyl-5-methoxy tryptamine or an analogue thereof,according to claim 1, wherein said analogue is selected fromagomelatine, 6-hydroxymelatonin, serotonin, 5 hydroxytryptophan or theirderivatives.
 3. N-acetyl-5-methoxy tryptamine or an analogue thereof,according to any one of claims 1-2, wherein said female mammaliansubject is a woman suffering from infertility or polyabortion. 4.N-acetyl-5-methoxy tryptamine or an analogue thereof, according to anyone of claims 1-3, wherein said topical administration is viaendometrial irrigation or uterine washing or endometrial washing. 5.N-acetyl-5-methoxy tryptamine or an analogue thereof, according to anyone of claims 1-4, wherein said topical administration is carried out ina single administration at the time of oocyte retrival. 6.N-acetyl-5-methoxy tryptamine or an analogue thereof, according to anyone of claims 1-5, wherein said N-acetyl-5-methoxy tryptamine oranalogue thereof is present in a concentration ranging from 4×10⁻⁹ g/mlto 25×10⁻⁹ g/ml, preferably greater than or equal to 10×10⁻⁹ g/ml. 7.N-acetyl-5-methoxy tryptamine or an analogue thereof, according to anyone of claims 1-6, for use with a contemporaneous systemicadministration of N-acetyl-5-methoxy tryptamine, HCG or progesterone, ora combination thereof, from the day of oocyte retrieval. 8.N-acetyl-5-methoxy tryptamine or an analogue thereof, according to anyone of the preceding claims, wherein the assisted reproductiontechniques are selected from the group consisting of planned copulation;intrauterine insemination (IUI); in vitro insemination and embryotransfer (FIVET); in vitro fertilization (IVF); intracytoplasmic sperminjection (ICSI), intracytoplasmic morphologically selected sperminjection (IMSI) techniques and Tesa-Tese (Testicular SpermAspiration-Extraction).
 9. Composition suitable for topicaladministration comprising N-acetyl-5-methoxy tryptamine or an analoguethereof, or a combination thereof as active ingredient, preferablyN-acetyl-5-methoxy tryptamine, in an effective amount in a mammaliansubject female in need of such treatment, along with one or morephysiologically acceptable excipients or adjuvants, for use in themedical or veterinary field in the assisted reproduction for theprevention of implantation failure into the uterus.
 10. Compositionaccording to claim 9, wherein said active ingredient is present in aconcentration ranging from 4×10⁻⁹ g/ml to 25×10⁻⁹ g/ml, preferablygreater than or equal to 10×10⁻⁹ g/ml.
 11. Composition according to anyone of claims 9-10, wherein said active ingredient is formulated as anendometrial irrigation or uterine washing or endometrial washing in amedium for cell culture to a final concentration ranging from 4×10⁻⁹g/ml to 25×10⁻⁹ g/ml, preferably greater than or equal to 10×10⁻⁹ g/ml.12. Composition according to claim 11, wherein said culture medium forblastocyst, comprises the following components: source of D-glucose;Antibiotic, preferably gentamicin; Human serum albumin; Essential andnon-essential amino acids, preferably L-taurine, buffer salts preferablyselected between: calcium salts: calcium lactate, calcium pantothenate;sodium salts: sodium chloride, sodium bicarbonate and sodium pyruvate;potassium salts: potassium chloride, potassium phosphate; magnesiumsalts: magnesium chloride, magnesium sulfate; Water; and has a pHbetween 7.5 and 7.8.
 13. Composition according to claim 12, wherein saidculture medium is the Sydney IVF® Blastocyst medium.
 14. Compositionaccording to any one of claims 9-10, wherein said active ingredient inthe above mentioned composition is formulated as endometrial irrigationor uterine washing or endometrial washing in physiological solution. 15.Composition according to claim 14, characterized in that it furthercomprises essential and non-essential amino acids and buffer salts tomaintain pH between 7-8, preferably 7.5-7.8.
 16. Medical device foruterine washing comprising a sterile container pre-filled or to befilled with a composition according to any one of claims 9-15. 17.Medical device according to claim 16, wherein the sterile container isdisposable.
 18. Medical device according to claim 16 or 17, wherein thesterile container is a syringe, a dispenser or a cartridge forself-injection devices.
 19. Medical device according to anyone of thepreceding claims, further comprising a sterile intrauterine catheter.20. Medical device according to anyone of claims 16-19, comprising adisposable sterile container pre-filled with a formulation based on aphysiological solution supplemented with melatonin, amino acids andbuffer salts to maintain pH between 7-8, preferably 7.5-7.8.
 21. Medicaldevice according to claim 20, wherein said formulation comprisesessential and non-essential amino acids and buffer salts preferablyselected between calcium, potassium and magnesium salts, and mixturesthereof.
 22. Medical device according to any one of claims 16-21,wherein melatonin has a concentration comprised between 4×10⁻⁹ g/ml and25×10⁻⁹ g/ml, preferably greater than or equal to 10×10⁻⁹ g/ml. 23.Medical device according to any one of claims 16-22, wherein saiddisposable sterile container is pre-filled with 1.5 ml volume ofphysiological solution comprising: 10×10⁻⁹ g/ml of melatonin essentialand non-essential amino acids calcium salts potassium salts magnesiumsalts.
 24. Medical device according to any one of claims 16-23, for usein the medical or veterinary field in the assisted reproduction for theprevention of implantation failure into the uterus.
 25. Cell culturemedium in vitro or in vivo, comprising: source of D-glucose; Antibiotic,preferably gentamicin; Human serum albumin; Essential and non-essentialamino acids, preferably L-taurine, buffer salts selected between:Calcium salts: calcium lactate, calcium pantothenate; Sodium salts:sodium chloride, sodium bicarbonate and sodium pyruvate; Potassiumsalts: potassium chloride, potassium phosphate; Magnesium salts:magnesium chloride, magnesium sulphate; and mixtures thereof; water;characterized in that it further comprises N-acetyl-5-methoxy tryptamineor an analogue thereof, or a combination thereof, wherein said activeingredient is present in a concentration ranging from 4×10⁻⁹ g/ml to25×10⁻⁹ g/ml, preferably greater than or equal to 10×10⁻⁹ g/ml.
 26. Useof the cell culture medium according to claim 25, for the growth ofpinopodes and the obtaining of an in vitro model study.